Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 7/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308137 | 0.95 | LYN (0.42) | TSPOSRCLYNBTKMTNR1A | |
| SCHEMBL4316480 | 0.90 | LYN (0.43) | TSPOSRCLYNBTKMTNR1A | |
| SCHEMBL4309383 | 0.88 | TSPO (0.44) | TSPOSRCLYNBTKMTNR1A | |
| SCHEMBL4307635 | 0.86 | TSPO (0.46) | TSPOSRCLYNBTKMTNR1A | |
| SCHEMBL4318316 | 0.85 | LYN (0.45) | TSPOSRCLYNBTKMTNR1A | |
| SCHEMBL4310962 | 0.83 | MAPT (0.40) | TSPOMTNR1AMTNR1BTP53RXFP1 | |
| SCHEMBL4305278 | 0.82 | LYN (0.42) | TSPOSRCLYNBTKMTNR1A | |
| SCHEMBL4311754 | 0.82 | MAPT (0.49) | TP53MAPT | |
| SCHEMBL4316778 | 0.81 | MAPT (0.38) | TSPOTP53RXFP1MAPT | |
| SCHEMBL4307754 | 0.80 | LYN (0.41) | TSPOSRCLYNBTKMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | TSPO 859/4885SRC 4275/4885LYN 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.